Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer's diseaseACTA NEUROPATHOLOGICAIF9.32024-02-066OAAI
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's diseaseALZHEIMERS RESEARCH & THERAPYIF7.62024-01-259OAAI
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheterTRANSLATIONAL NEURODEGENERATIONIF15.22023-05-1213OAAI
Screening of?2Receptor Ligands and In Vivo Evaluation of 11C-Labeled 6,7-Dimethoxy-2-[4-(4-methoxyphenyl)butan-2-yl]-1,2,3,4-tetrahydroisoquinoline for Potential Use as a ?2ReceptorBrain PET TracerJOURNAL OF MEDICINAL CHEMISTRYIF6.82022-04-1113PRE
Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's DiseaseACS MEDICINAL CHEMISTRY LETTERSIF42021-08-0933OAAI
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modificationALZHEIMERS & DEMENTIAIF11.12021-02-0857OA
The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease阿尔茨海默氏病突触损伤或丧失的生物标志物的临床前景ALZHEIMERS RESEARCH & THERAPYIF7.62020-03-02213OAAI
The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biologyBIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCERIF8.32016-12-0198PREAI